세계의 스캐폴드 프리 3D 세포배양 시장 보고서(2025년)
Scaffold Free 3D Cell Culture Global Market Report 2025
상품코드 : 1889566
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,505,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,403,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,301,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

스캐폴드 프리 3D 세포배양 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 7억 5,000만 달러로 평가되었고, 2025년에는 8억 5,000만 달러에 달할 것으로 추정되며, CAGR 12.4%로 성장이 예상되고 있습니다. 지금까지의 성장은 독성시험에서의 스캐폴드 프리 모델 이용 증가, 비용 효율적인 전임상 모델 수요 증가, 예측 정밀도가 높은 약제 시험에 대한 수요 증가, 학술계 및 산업계에서의 3D 연구 확대, 그리고 선진적인 세포배양 연구에 대한 정부 자금 증가에 기인하고 있습니다.

스캐폴드 프리 3D 세포배양 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 13억 3,000만 달러에 달할 것으로 예측되며, CAGR 12.0%로 성장할 전망입니다. 예측 기간의 성장 요인으로는 환자 유래 유기체의 채용 확대, 개별화 약물 스크리닝의 필요성 증가, 스캐폴드 프리 구상체 분석 수요 증가, 의약품 연구 파이프라인 확대, 합리적인 의료 용도에 있어서의 진보 등을 들 수 있습니다. 예측 기간 동안 예상되는 주요 동향은 마이크로플루이딕스 3D 배양 시스템의 혁신, 바이오리액터 및 자동화 플랫폼의 기술적 진보, 공배양 및 다세포 모델의 개발, 질병 특이적 오가노이드의 연구개발 증가, 3D 배양을 위한 고 컨텐츠 이미징 및 분석의 진전을 포함합니다.

맞춤형 의료의 성장은 향후 수년간 스캐폴드 프리 3D 세포배양 시장의 확대를 이끌 것으로 예측됩니다. 맞춤형 의료는 개인의 유전적 요인, 환경 요인, 생활 습관에 따라 치료법 및 의료 판단을 사용자 정의합니다. 그 성장은 유전체학, 생명공학, 데이터 분석의 진보에 의해 촉진되어 보다 정밀하고 효과적인 맞춤형 치료를 가능하게 하고 있습니다. 스캐폴드 프리 3D 세포배양 기술은 환자 고유의 조직 모델을 창출함으로써 맞춤형 의료를 지원하고 정확한 약물 시험과 개인화된 치료 전략을 가능하게 합니다. 예를 들어 2024년 2월 미국 비영리 단체 '맞춤형 의료연합'이 보고한 바에 따르면 2023년에는 FDA가 희소질환 환자를 위한 신규 맞춤형 치료를 16건 승인하였고, 2022년 6건에서 증가했습니다. 따라서 맞춤형 의료의 확대가 스캐폴드 프리 3D 세포배양 시장의 성장을 견인하고 있습니다.

스캐폴드 프리 3D 세포배양 시장의 주요 기업은 창약이나 암 연구의 효율화를 도모하기 위해, 스페로이드 형성이나 모니터링 등의 분야에서 기술 혁신을 진행하고 있습니다. 광학적으로 투명한 플라스크 밑면, 균일한 마이크로 캐비티 설계, 하이 스루풋 포맷 등의 기술로 3D 세포배양의 가시성, 재현성, 스케일 업이 향상되었습니다. 예를 들어, 2024년 2월에는 미국에 본사를 둔 생명 과학 기업인 코닝사가 '코닝 엘프라지아 12K 플라스크'를 발표했습니다. 이 플라스크는 플라스크 당 약 1만 2,000개의 균일한 스페로이드의 생산을 지원하며 기존의 96웰 플레이트와 비교하여 스페로이드 크기의 균일성 향상, 재현성 향상 및 수율 증가를 실현합니다. 종양세포, 정상세포, 초대세포 등 다양한 세포 유형에 대응하고 있으며, 약제 스크리닝, 암 연구, 선진적 치료법의 개발에 유용합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Scaffold-free 3D cell culture is a technique that enables cells to grow and self-assemble into three-dimensional structures without relying on external scaffolding materials. This method depends on the cells' natural ability to adhere to one another and form spheroids or organoid-like structures, more accurately replicating the architecture and function of native tissues. It provides a physiologically relevant environment for studying cell behavior, tissue development, and drug responses.

The main product types in scaffold-free 3D cell culture include 3D cell culture platforms, 3D bioprinting products, 3D cell culture kits, and microfluidic devices. 3D cell culture platforms are advanced systems that support cell growth and interaction in three dimensions without scaffolding materials, closely simulating natural tissue architecture and function. Key cellular components include stem cells, adherent cell cultures, suspension cell cultures, and immune cells. Major techniques used are the hanging drop method, magnetic levitation, and microfluidics. Key applications include drug discovery, regenerative medicine, tissue engineering, oncology research, and stem cell research, with primary end users comprising academic research institutions, pharmaceutical and biotechnology companies, contract research organizations (CROs), and clinics and hospitals.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The scaffold free 3D cell culture market research report is one of a series of new reports from The Business Research Company that provides scaffold free 3D cell culture market statistics, including the scaffold free 3D cell culture industry global market size, regional shares, competitors with the scaffold free 3D cell culture market share, detailed scaffold free 3D cell culture market segments, market trends, and opportunities, and any further data you may need to thrive in the scaffold free 3D cell culture industry. This scaffold free 3D cell culture market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The scaffold free 3D cell culture market size has grown rapidly in recent years. It will grow from $0.75 billion in 2024 to $0.85 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. Growth during the historic period can be attributed to increasing use of scaffold-free models in toxicity testing, the growing need for cost-effective preclinical models, rising demand for more predictive drug testing, the expansion of academic and industrial 3D research, and increased government funding for advanced cell-culture studies.

The scaffold free 3D cell culture market size is expected to see rapid growth in the next few years. It will grow to $1.33 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. Growth in the forecast period can be attributed to the growing adoption of patient-derived organoids, rising requirements for personalized drug screening, increasing demand for scaffold-free spheroid assays, expansion of pharmaceutical research pipelines, and advancements in rational medicine applications. Major trends expected in the forecast period include innovations in microfluidic 3D culture systems, technological advancements in bioreactors and automated platforms, developments in co-culture and multicellular models, increased research and development in disease-specific organoids, and progress in high-content imaging and analysis for 3D cultures.

The growth of personalized medicine is expected to drive the expansion of the scaffold-free 3D cell culture market in the coming years. Personalized medicine tailors treatments and healthcare decisions based on individual genetic, environmental, and lifestyle factors. Its growth is fueled by advances in genomics, biotechnology, and data analytics, enabling more precise and effective individualized therapies. Scaffold-free 3D cell culture supports personalized medicine by creating patient-specific tissue models, allowing accurate drug testing and tailored therapeutic strategies. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from six approved in 2022. Therefore, the expansion of personalized medicine is driving growth in the scaffold-free 3D cell culture market.

Major companies in the scaffold-free 3D cell culture market are innovating in areas such as spheroid formation and monitoring to enhance efficiency in drug discovery and cancer research. Technologies like optically clear flask bottoms, uniform microcavity designs, and high-throughput formats enable better visualization, reproducibility, and scale of 3D cell cultures. For instance, in February 2024, Corning Incorporated, a US-based life sciences company, introduced the Corning Elplasia 12K flask. This flask supports the production of approximately 12,000 uniform spheroids per flask, offering greater consistency in spheroid size, improved reproducibility, and higher yields compared to traditional 96-well plates. It is compatible with tumor, normal, and primary cell types, making it valuable for drug screening, cancer research, and advanced therapy development.

In January 2025, Merck KGaA, a Germany-based healthcare and life sciences company, acquired HUB Organoids Holding B.V. to strengthen its scaffold-free 3D cell culture capabilities. Through this acquisition, Merck aims to integrate HUB Organoids' patient-derived organoid technology to accelerate and enhance drug discovery and personalized medicine applications. HUB Organoids, based in the Netherlands, specializes in patient-derived organoid models that closely replicate human tissue structure and function for research and therapeutic purposes.

Major companies operating in the scaffold free 3d cell culture market are Thermo Fisher Scientific Inc., Merck KGaA, Corning Incorporated, Lonza Group AG, Sartorius AG, Hamilton Company, CELLINK AB, Creative Bioarray Inc., InSphero AG, Creative Biolabs Inc., Mimetas B.V., REPROCELL Inc., Synthecon Incorporated, Advanced Solutions Life Sciences LLC, Cherry Biotech SAS, celVivo ApS, Elveflow, Guangzhou Jet Bio-Filtration Co. Ltd., Organovo Holdings Inc., Alfa Cytology Co. Ltd.

North America was the largest region in the scaffold free 3D cell culture market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in scaffold free 3D cell culture report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the scaffold free 3D cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The scaffold free 3D cell culture market consists of sales of 3D cell culture platforms, 3D bioprinting products, 3D cell culture kits, microfluidic devices, spheroid culture plates, magnetic levitation kits, hanging drop plates, organoid culture media, cell culture consumables, and specialized culture ware. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Scaffold Free 3D Cell Culture Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on scaffold free 3d cell culture market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for scaffold free 3d cell culture ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The scaffold free 3d cell culture market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Scaffold Free 3D Cell Culture Market Characteristics

3. Scaffold Free 3D Cell Culture Market Trends And Strategies

4. Scaffold Free 3D Cell Culture Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Scaffold Free 3D Cell Culture Growth Analysis And Strategic Analysis Framework

6. Scaffold Free 3D Cell Culture Market Segmentation

7. Scaffold Free 3D Cell Culture Market Regional And Country Analysis

8. Asia-Pacific Scaffold Free 3D Cell Culture Market

9. China Scaffold Free 3D Cell Culture Market

10. India Scaffold Free 3D Cell Culture Market

11. Japan Scaffold Free 3D Cell Culture Market

12. Australia Scaffold Free 3D Cell Culture Market

13. Indonesia Scaffold Free 3D Cell Culture Market

14. South Korea Scaffold Free 3D Cell Culture Market

15. Western Europe Scaffold Free 3D Cell Culture Market

16. UK Scaffold Free 3D Cell Culture Market

17. Germany Scaffold Free 3D Cell Culture Market

18. France Scaffold Free 3D Cell Culture Market

19. Italy Scaffold Free 3D Cell Culture Market

20. Spain Scaffold Free 3D Cell Culture Market

21. Eastern Europe Scaffold Free 3D Cell Culture Market

22. Russia Scaffold Free 3D Cell Culture Market

23. North America Scaffold Free 3D Cell Culture Market

24. USA Scaffold Free 3D Cell Culture Market

25. Canada Scaffold Free 3D Cell Culture Market

26. South America Scaffold Free 3D Cell Culture Market

27. Brazil Scaffold Free 3D Cell Culture Market

28. Middle East Scaffold Free 3D Cell Culture Market

29. Africa Scaffold Free 3D Cell Culture Market

30. Scaffold Free 3D Cell Culture Market Competitive Landscape And Company Profiles

31. Scaffold Free 3D Cell Culture Market Other Major And Innovative Companies

32. Global Scaffold Free 3D Cell Culture Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Scaffold Free 3D Cell Culture Market

34. Recent Developments In The Scaffold Free 3D Cell Culture Market

35. Scaffold Free 3D Cell Culture Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기